REGENX views licensing and partnership development as a central part of our mission to enable the ongoing development of novel AAV vector-based therapeutics.We are very interested in partnering with biotechnology companies as well as academic researchers that complement our expertise and NAV Technology with knowledge of specific molecular pathways and targets of disease for the development of therapeutics.

REGENX is committed to forming alliances with leading industry and research institutions to develop therapeutic applications for diseases that have serious unmet need. We will grant licenses for the development and commercialization of novel AAV vector based therapeutics for specified molecular targets and for basic research and development.

If you have interest in discussing licensing or partnering opportunities with REGENX, please contact Vit Vasista at